NEU Stock Overview
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Neuren Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$7.96 |
| 52 Week High | AU$9.18 |
| 52 Week Low | AU$3.04 |
| Beta | 1.6 |
| 1 Month Change | 0.13% |
| 3 Month Change | 8.59% |
| 1 Year Change | 144.17% |
| 3 Year Change | 181.27% |
| 5 Year Change | 165.33% |
| Change since IPO | 7.57% |
Recent News & Updates
Recent updates
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Jan 07
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
Sep 06Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth
May 31We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn
Feb 03Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation
Aug 06We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth
May 05Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)
Feb 19Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?
Jan 04
Shareholder Returns
| NEU | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -9.6% | -4.4% | 0.6% |
| 1Y | 144.2% | -25.2% | 3.5% |
Return vs Industry: NEU exceeded the Australian Pharmaceuticals industry which returned -25.2% over the past year.
Return vs Market: NEU exceeded the Australian Market which returned 3.5% over the past year.
Price Volatility
| NEU volatility | |
|---|---|
| NEU Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: NEU is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: NEU's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Jon Pilcher | https://www.neurenpharma.com |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes.
Neuren Pharmaceuticals Limited Fundamentals Summary
| NEU fundamental statistics | |
|---|---|
| Market Cap | AU$1.00b |
| Earnings (TTM) | -AU$6.88m |
| Revenue (TTM) | AU$3.20m |
313.6x
P/S Ratio-145.7x
P/E RatioIs NEU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEU income statement (TTM) | |
|---|---|
| Revenue | AU$3.20m |
| Cost of Revenue | AU$7.17m |
| Gross Profit | -AU$3.97m |
| Other Expenses | AU$2.92m |
| Earnings | -AU$6.88m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.055 |
| Gross Margin | -124.15% |
| Net Profit Margin | -215.33% |
| Debt/Equity Ratio | 0% |
How did NEU perform over the long term?
See historical performance and comparison